Free tool
FAERS Monitor: Tazverik
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211723 or its brand name (Tazverik, Tazemetostat Hydrobromide). Reports on generic versions are filed under their own applications.
Reports
1,622
Serious
721
44% of reports
Hospitalization
324
Death reported
216
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use335
- fatigue326
- disease progression305
- nausea235
- product dose omission issue212
- death132
- diarrhoea123
- decreased appetite97
- vomiting95
- asthenia83
- constipation80
- headache74
- covid-1972
- drug ineffective71
- alopecia69
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 3 |
| 2018 | 11 |
| 2019 | 6 |
| 2020 | 81 |
| 2021 | 256 |
| 2022 | 395 |
| 2023 | 316 |
| 2024 | 205 |
| 2025 | 242 |
| 2026 | 107 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,537 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 305 | 33.5 | 30.3 | 9,616 |
| product dose omission issueSignal | 212 | 9.4 | 8.3 | 1,595 |
| fatigueSignal | 326 | 5.4 | 4.9 | 1,219 |
| decreased appetiteSignal | 97 | 5.4 | 4.5 | 349 |
| covid-19Signal | 72 | 5.3 | 4.2 | 250 |
| off label useSignal | 335 | 5.0 | 4.5 | 1,101 |
| constipationSignal | 80 | 4.8 | 3.8 | 236 |
| alopeciaSignal | 69 | 4.6 | 3.6 | 190 |
| nauseaSignal | 235 | 3.9 | 3.4 | 512 |
| astheniaSignal | 83 | 2.9 | 2.3 | 101 |
| vomitingSignal | 95 | 2.6 | 2.2 | 96 |
| diarrhoeaSignal | 123 | 2.5 | 2.1 | 110 |
| death | 132 | 2.0 | 1.7 | 66 |
| headache | 74 | 1.5 | 1.2 | 13 |
| drug ineffective | 71 | 0.7 | 0.6 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.